| |
J & J - Novel Coronavirus, SARS-CoV-2
|
| |
| |
Lack of evidence to support use of darunavir-based treatments for SARS-CoV-2
• Anecdotal, unsubstantiated reports claim that darunavir has antiviral effect against COVID-19
• Johnson & Johnson has no evidence that darunavir has any effect against SARS-CoV-2, the virus that causes COVID-19
• Johnson & Johnson is screening its antiviral compounds, including darunavir, to determine potential in vitro effect against SARS-CoV-2
• We are partnering with multiple organizations to support the development of research programs and fast-track solutions for COVID-19
https://www.jnj.com/lack-of-evidence-to-support-darunavir-based-hiv-treatments-for-coronavirus
J & J - Novel Coronavirus, SARS-CoV-2
https://www.jnj.com/coronavirus
Johnson & Johnson's Response to the Outbreak
• On December 31, 2019, several cases of pneumonia in Wuhan City, Hubei Province of China were reported to the World Health Organization (WHO). The novel virus, now known as SARS-CoV-2, has since spread across China and to other countries and territories. The WHO has named the disease caused by this novel coronavirus: COVID-19.
• Johnson & Johnson is mobilizing resources of its Janssen Pharmaceutical Companies in response to the outbreak to develop a possible preventive vaccine candidate against SARS-CoV-2, leveraging Janssen's AdVac® and PER.C6® technology, that provide the ability to rapidly upscale production of the optimal vaccine candidate. These are the same technologies that were used in the development and manufacturing of Janssen's investigational Ebola vaccine, which is currently deployed in the Democratic Republic of the Congo and Rwanda, and were also used to construct the Company's Zika, RSV and HIV vaccine candidates.
• The Company announced on February 18, 2020 that Janssen Pharmaceutical Companies will expand its existing partnership with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health & Human Services, to seek treatment solutions for COVID-19. These efforts, in addition to the ongoing development of a potential vaccine candidate with BARDA, build on Johnson & Johnson's multipronged response to the COVID-19 outbreak.
• The Company's multi-pronged approach also includes a review of known pathways in coronavirus pathophysiology to determine whether previously tested medicines can be used to help patients survive COVID-19 and reduce the severity of disease in non-lethal cases.
• Johnson & Johnson has robust business continuity plans in place across its global supply chain network to prepare for unforeseen events like the coronavirus outbreak. These steps include maintaining critical inventory at major distribution centers away from high-risk areas and working with external suppliers to support our preparedness plans. We are closely monitoring product demand and supply levels across our global network to ensure adequate and effective distribution, and working diligently to meet patient, customer and consumer need.
COVID-19: A Timeline
This is not the first time that a member of the large family of coronaviruses (CoVs) has led to an outbreak of infections among humans. The crises involving severe acute respiratory syndrome (SARS) in China in 2003 and Middle East respiratory syndrome (MERS) in 2012 were both caused by CoVs. J&J is mobilizing resources to find solutions for COVID-19.
|
|
| |
| |
|
|
|
